Short article for Journal of Neuroscience Nursing

ICONS II: Identifying Continence OptioNs after Stroke randomised controlled trial.


Background

Stroke is one of the two greatest causes of death worldwide, accounting for 10% of deaths in 2010. Globally, there were 16.9 million people with a first stroke and 33 million stroke survivors in 2010 [1]. In the UK, up to 95,000 people survive a stroke per annum [1]. Incidence is unlikely to decline given the ageing population, and prevalence continues to rise.

Urinary incontinence (UI) is defined as the complaint of any involuntary leakage of urine [2]. UI affects around half of stroke survivors in the acute phase [3, 4]. As many as 44% and 38% of stroke survivors remain incontinent at 3 months and 1 year respectively [5]. UI often presents as a new problem after stroke or, if pre-existing, worsens significantly, adding to the disability and helplessness caused by neurological deficits [6].

The more severe the stroke, the greater the likelihood of UI [7]; other factors include older age or cognitive impairment [8]. Urge incontinence (involuntary leakage immediately following, or concurrent with, an urgent sensation of needing to void) is the most common type after stroke [9] and is generally the result of detrusor over-activity. Stroke patients with UI have considerably worse outcomes: there is a clear association between UI after stroke and death, disability and an increased likelihood of discharge into residential care [7, 10, 11].

UI is distressing for individuals and families and depression is twice as common in stroke survivors who are incontinent [12, 13]. Negative social consequences for survivors and carers cannot be ignored: both may become isolated and marginalised [14]. Continuing incontinence is associated with poor outcome in both stroke survivors and carers [3, 15-17].

It is important to study UI in this population as symptoms are more severe and have more of an effect compared with other groups of people [6]. Furthermore, associated stroke impairments compound difficulties with bladder control with motor, visual or speech problems making the task of accessing toilet facilities a challenge [18].

Incontinence is often poorly managed, even by specialist teams working on recognised stroke units [19]. Failure to address the problem may be because of lack of knowledge of the mechanisms of UI or emphasis on management in primary care [20]. The opportunity for early intervention to enhance natural recovery in secondary care is therefore being missed.

Furthermore, despite clinical guidelines stating indwelling urethral catheters (IUCs) should only be used to relieve retention [21], there is over-reliance on catheterisation as a management strategy for UI in stroke units, especially in the acute phase [19, 22]. This puts patients at risk of IUC-associated urinary tract infection and its consequences [23-26], including increased morbidity, mortality and resource use [24, 27, 28]. In our ICONS: Identifying Continence OptioNs after Stroke feasibility trial, 48% of patients in intervention arms were catheterised in the acute phase [29]. Urinary tract infection and antibiotic use are considerably higher in patients with IUCs, with increasing risk of infection associated with later removal [30].
The update of our Cochrane review ‘Treatment of urinary incontinence after stroke in adults’ has revealed several new studies [31-34], however the conclusion, that data from the available trials are insufficient to guide continence care, is unlikely to change without a definitive trial. We have received funding for a trial from the UK National Institute for Health Research Health Technology Assessment Programme to address this clear gap in the evidence base.

The ICONS II trial

The ICONS II trial will build on our recent feasibility trial [29, 35] and rigorously test a programme designed to assess and treat UI after stroke in hospital. It will answer the research question “Is a systematic voiding programme a clinically effective and cost effective treatment for urinary incontinence (UI) in patients with urinary incontinence after stroke in secondary care?”

ICONS II is a pragmatic, multicentre, randomised parallel group trial to compare the effectiveness of the systematic voiding programme (n=512) with usual care (n=512) in reducing the severity of UI in patients with stroke and UI in secondary care. The trial includes a mixed methods process evaluation investigating fidelity to the intervention and usual care, and an economic evaluation of the systematic voiding programme compared with usual care.

We are currently recruiting stroke units in England and Wales to participate in the trial, and will begin recruiting participants in July 2018.

For further information about the trial, please contact Dr Lois Thomas, lthomas@uclan.ac.uk, +44(0) 1772 893643.

732 words

Funding acknowledgement: This research was funded by the NIHR HTA Programme (16/111/31)

Department of Health disclaimer: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health
References